Biomarin Pharmaceutical Inc BMRN Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,850

Price:

--
Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

7,870

Price:

--
Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

21,190

Price:

--
Sep 13, 2024 (filed on Sep 17, 2024)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-12,098

Price:

$84.90
Aug 13, 2024 (filed on Aug 15, 2024)

Insider Name:

Burkhart Erin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-714

Price:

$90.00
Jun 28, 2024 (filed on Jul 01, 2024)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-588

Price:

$82.33
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy Common Stock)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,047

Price:

--
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,168

Price:

$76.41
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

5,047

Price:

$63.10
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Meier Richard A

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy Common Stock)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-6,600

Price:

--

Filings by filing date

Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy Common Stock)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

49,850

Price:

--
Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

7,870

Price:

--
Sep 30, 2024 (filed on Oct 01, 2024)

Insider Name:

Friberg Gregory R

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

21,190

Price:

--
Sep 13, 2024 (filed on Sep 17, 2024)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-12,098

Price:

$84.90
Apr 30, 2024 (filed on Sep 17, 2024)

Insider Name:

Fuchs Henry J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

300

Price:

$68.65
Aug 13, 2024 (filed on Aug 15, 2024)

Insider Name:

Burkhart Erin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-714

Price:

$90.00
Jun 28, 2024 (filed on Jul 01, 2024)

Insider Name:

Mueller Brian

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-588

Price:

$82.33
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Stock Option (Right to Buy Common Stock)

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,047

Price:

--
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3

# or value acquired/disposed of:

-4,168

Price:

$76.41
Jun 03, 2024 (filed on Jun 04, 2024)

Insider Name:

Heron Elaine J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

5,047

Price:

$63.10

News

Biz Brief

Sector: Healthcare	Industry: Pharmaceuticals

See Regulatory Filings on SEC

Company Contact

Address:	770 Lindaro Street SAN RAFAEL CA 94901
Tel:	N/A
Website:	https://www.biomarin.com
IR:	See website

Key People

Alexander Hardy President, Chief Executive Officer, Director	Brian R. Mueller Chief Financial Officer, Executive Vice President - Finance	Henry J. Fuchs President - Worldwide Research and Development
C. Greg Guyer Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer	G. Eric Davis Executive Vice President, Secretary, Chief Legal Officer	Greg Friberg Executive Vice President, Chief Research & Development Officer
Cristin Hubbard Executive Vice President, Chief Commercial Officer	James H. Sabry Executive Vice President, Chief Business Officer	Erin Burkhart Group Vice President, Chief Accounting Officer

Business Overview

BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company, which is engaged in developing and commercializing therapies that address the root cause of genetic conditions. BioMarin's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Voxzogo is a once daily injection analog of C-type Natriuretic Peptide (CNP) for the treatment of achondroplasia. Brineura is a recombinant human tripeptidyl peptidase 1 (TPP1) for the treatment of patients with CLN2, a form of Batten disease.

Financial Overview

For the six months ended 30 June 2024, Biomarin Pharmaceutical Inc revenues increased 14% to $1.36B. Net income increased 83% to $195.8M. Revenues reflect Voxzogo segment increase from $113.3M to $336.8M, Vimizim1 segment increase from $177.4M to $370.5M, Europe segment increase from $183.4M to $416.7M, United States segment increase from $191.7M to $420.4M. Net income benefited from Interest Income increase of 59% to $39.2M (income).

Employees:	3,401 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$12,841M as of Jun 30, 2024
Annual revenue (TTM):	$2,588M as of Jun 30, 2024
EBITDA (TTM):	$384.18M as of Jun 30, 2024
Net annual income (TTM):	$256.59M as of Jun 30, 2024
Free cash flow (TTM):	$212.80M as of Jun 30, 2024
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	190,382,822 as of Jul 31, 2024
Index Membership:	S&P 400 Mid Cap
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization